Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Lys05 - A Promising Autophagy Inhibitor in the Radiosensitization Battle: Phosphoproteomic Perspective

M. Ondrej, L. Cechakova, I. Fabrik, J. Klimentova, A. Tichy

. 2020 ; 17 (4) : 369-382. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21012409

BACKGROUND: Autophagy is a crucial factor contributing to radioresistance during radiotherapy. Although Lys05 has proven its ability to improve the results of radiotherapy through the inhibition of autophagy, molecular mechanisms of this inhibition remain elusive. We aimed to describe the molecular mechanisms involved in Lys05-induced inhibition of autophagy. MATERIALS AND METHODS: Radioresistant human non-small cell lung carcinoma cells (H1299, p53-negative) and methods of quantitative phosphoproteomics were employed to define the molecular mechanisms involved in Lys05-induced inhibition of autophagy. RESULTS: We confirmed that at an early stage after irradiation, autophagy was induced, whereas at a later stage after irradiation, it was inhibited. The early-stage induction of autophagy was characterized mainly by the activation of biosynthetic and metabolic processes through up- or down-regulation of the critical autophagic regulatory proteins Sequestosome-1 (SQSTM1) and proline-rich AKT1 substrate 1 (AKT1S1). The late-stage inhibition of autophagy was attributed mainly to down-regulation of Unc-51 like autophagy-activating kinase 1 (ULK1) through phosphorylation at Ser638. CONCLUSION: This work contributes to emerging phosphoproteomic insights into autophagy-mediated global signaling in lung cancer cells, which might consequently facilitate the development of precision medicine therapeutics.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21012409
003      
CZ-PrNML
005      
20210507101838.0
007      
ta
008      
210420s2020 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/cgp.20196 $2 doi
035    __
$a (PubMed)32576582
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Ondrej, Martin $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defense in Brno, Hradec Kralove, Czech Republic
245    10
$a Lys05 - A Promising Autophagy Inhibitor in the Radiosensitization Battle: Phosphoproteomic Perspective / $c M. Ondrej, L. Cechakova, I. Fabrik, J. Klimentova, A. Tichy
520    9_
$a BACKGROUND: Autophagy is a crucial factor contributing to radioresistance during radiotherapy. Although Lys05 has proven its ability to improve the results of radiotherapy through the inhibition of autophagy, molecular mechanisms of this inhibition remain elusive. We aimed to describe the molecular mechanisms involved in Lys05-induced inhibition of autophagy. MATERIALS AND METHODS: Radioresistant human non-small cell lung carcinoma cells (H1299, p53-negative) and methods of quantitative phosphoproteomics were employed to define the molecular mechanisms involved in Lys05-induced inhibition of autophagy. RESULTS: We confirmed that at an early stage after irradiation, autophagy was induced, whereas at a later stage after irradiation, it was inhibited. The early-stage induction of autophagy was characterized mainly by the activation of biosynthetic and metabolic processes through up- or down-regulation of the critical autophagic regulatory proteins Sequestosome-1 (SQSTM1) and proline-rich AKT1 substrate 1 (AKT1S1). The late-stage inhibition of autophagy was attributed mainly to down-regulation of Unc-51 like autophagy-activating kinase 1 (ULK1) through phosphorylation at Ser638. CONCLUSION: This work contributes to emerging phosphoproteomic insights into autophagy-mediated global signaling in lung cancer cells, which might consequently facilitate the development of precision medicine therapeutics.
650    _2
$a aminochinoliny $x farmakologie $7 D000634
650    12
$a autofagie $7 D001343
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x metabolismus $x patologie $x radioterapie $7 D002289
650    _2
$a lidé $7 D006801
650    _2
$a nádory plic $x farmakoterapie $x metabolismus $x patologie $x radioterapie $7 D008175
650    _2
$a fosfoproteiny $x analýza $x metabolismus $7 D010750
650    _2
$a fosforylace $7 D010766
650    _2
$a polyaminy $x farmakologie $7 D011073
650    _2
$a proteom $x analýza $x metabolismus $7 D020543
650    _2
$a radiosenzibilizující látky $x farmakologie $7 D011838
650    _2
$a signální transdukce $7 D015398
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
700    1_
$a Cechakova, Lucie $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defense in Brno, Hradec Kralove, Czech Republic
700    1_
$a Fabrik, Ivo $u Department of Molecular Biology and Pathology, Faculty of Military Health Sciences, University of Defense in Brno, Hradec Kralove, Czech Republic
700    1_
$a Klimentova, Jana $u Department of Molecular Biology and Pathology, Faculty of Military Health Sciences, University of Defense in Brno, Hradec Kralove, Czech Republic
700    1_
$a Tichy, Ales $u Department of Radiobiology, Faculty of Military Health Sciences, University of Defense in Brno, Hradec Kralove, Czech Republic ales.tichy@unob.cz
773    0_
$w MED00180194 $t Cancer genomics & proteomics $x 1790-6245 $g Roč. 17, č. 4 (2020), s. 369-382
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32576582 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210420 $b ABA008
991    __
$a 20210507101838 $b ABA008
999    __
$a ok $b bmc $g 1650723 $s 1132788
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 17 $c 4 $d 369-382 $e - $i 1790-6245 $m Cancer genomics & proteomics $n Cancer Genomics Proteomics $x MED00180194
LZP    __
$a Pubmed-20210420

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...